1	Brain Total Creatine Differs Between Primary
2	Progressive Aphasia (PPA) Subtypes and Correlates
2	with Disease Severity
4	
5	
6	Kathleen E. Hunfeld ^{a,b} . Helge J. Zöllner ^{a,b} . Georg Oeltzschner ^{a,b} . Havden W. Hvatt ^c . Olivia
7	Harmond lessica Gallagos ^d Steve C N Huj a,b Ashley D Harris e,f Richard A E Edden a,b
8	and Kyrana Tsapkini ^{d,g*}
9 10 11	
12 13 14	^a Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
15 16 17	^b F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, USA
18 19	^c Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
20 21	^d Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
22 23	^e Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
24 25	^f Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada
26 27 28 29 30	⁹ Department of Cognitive Science, Johns Hopkins University, Baltimore, MD, USA
31	Corresponding Author: Kyrana Tsapkini, PhD
32	Departments of Neurology and Cognitive Science
33 34	Phipps 488, 600 N Wolfe Street
35 36	Baltimore, MD 21287 <u>Email</u> : tsapkini@jhmi.edu
37 38 39	
40	Running Title: BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

41 Highlights

- No prior work has examined differences in brain metabolite levels for PPA subtypes.
- Total creatine (tCr) levels were lowest in IvPPA and highest in svPPA.
- tCr levels differentiated lvPPA from svPPA diagnosis.
- Higher tCr and lower Glx in the left IFG correlated with greater disease severity.
- Changes in cellular energy and excitatory processes may relate to PPA pathology.

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

47 Abstract

48	Primary progressive aphasia (PPA) is comprised of three subtypes: logopenic (IvPPA),
49	non-fluent (nfvPPA), and semantic (svPPA). We used magnetic resonance spectroscopy (MRS)
50	to measure tissue-corrected metabolite levels in the left inferior frontal gyrus (IFG) and right
51	sensorimotor cortex (SMC) from 61 PPA patients. We aimed to: 1) characterize subtype
52	differences in metabolites; and 2) test for metabolite associations with symptom severity. tCr
53	differed by subtype across the left IFG and right SMC. tCr levels were lowest in lvPPA and
54	highest in svPPA. tCr levels predicted lvPPA versus svPPA diagnosis. Higher IFG tCr and lower
55	Glx correlated with greater disease severity. As tCr is involved in brain energy metabolism,
56	svPPA pathology might involve changes in specific cellular energy processes. Perturbations to
57	cellular energy homeostasis in language areas may contribute to symptoms. Reduced cortical
58	excitatory capacity (i.e., lower Glx) in language regions may also contribute to symptoms. Thus,
59	tCr may be useful for differentiating between PPA subtypes, and both tCr and GIx might have
60	utility in understanding PPA mechanisms and tracking progression.
61	

- 62 **Keywords:** Primary Progressive Aphasia (PPA), creatine (tCr), glutamate+glutamine (Glx),
- 63 magnetic resonance spectroscopy (MRS), Point RESolved Spectroscopy (PRESS)

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

4

64 **1. Introduction**

65 Primary progressive aphasia (PPA) is a devastating neurodegenerative condition 66 characterized by prominent declines in language function (Gorno-Tempini et al., 2011; 67 Mesulam, 1982). Symptoms usually begin in middle age (around 40-60 years), worsen over 68 time, and may later extend to other cognitive domains (Gorno-Tempini et al., 2011; Grossman, 69 2010: Mesulam, 1982). PPA thus considerably impacts quality of life, in addition to shortening 70 life expectancy; average life expectancy after symptom onset is only about 7-12 years (Tastevin 71 et al., 2021). Critically, aside from some symptom improvement with behavioral therapy 72 (Pagnoni et al., 2021) or neuromodulation (Cotelli et al., 2020; Tsapkini et al., 2018), there 73 remain no disease-modifying treatments for PPA. Therefore, it is becoming increasingly 74 imperative to improve scientific understanding of PPA pathology to identify biomarkers of 75 disease progression as well as potential therapeutic targets. 76 Consistent with their language symptoms, those with PPA typically display cortical 77 atrophy in the left hemisphere, particularly in brain regions related to language function

78 (Rogalski et al., 2014). However, PPA is a heterogeneous disorder associated with both varied 79 symptoms and varied pathology. As such, expert consensus has divided PPA into three main 80 subtypes (Gorno-Tempini et al., 2011) (along with mixed or unclassified cases): 1) logopenic 81 variant PPA (IvPPA) is characterized by deficits in word retrieval (i.e., producing the intended 82 word) and difficulty repeating words and sentences; 2) non-fluent variant PPA (nfvPPA) is 83 characterized by deficits in grammar and speech production and/or slow, effortful, and distorted 84 (apraxic) speech, but preserved word comprehension and naming; and 3) semantic variant PPA 85 (svPPA) is characterized by severe deficits in single-word comprehension and naming, but 86 preserved grammar and fluency (i.e., these individuals tend to produce "empty" speech).

These three subtypes have been linked to different cortical atrophy patterns and different pathology. Atrophy is most prominent in the left posterior temporal and inferior parietal lobes in lvPPA, left posterior frontal and fronto-insular cortex in nfvPPA, and anterior temporal lobes (left

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

5

90	dominant but usually bilateral) in svPPA (Gorno-Tempini et al., 2011). LvPPA is most often
91	associated with Alzheimer's disease (AD) pathology (e.g., PET-PIB positivity, decreased A β 42,
92	and elevated tau in the cerebrospinal fluid) (Mesulam et al., 2008; Rabinovici et al., 2008),
93	nfvPPA is most often associated with tau-positive pathology (Josephs et al., 2006; Knibb et al.,
94	2006; Mesulam et al., 2008), and svPPA is most often associated with ubiquitin/TDP43-positive
95	frontotemporal lobar degeneration (Davies et al., 2005; Grossman, 2010; Hodges et al., 2004;
96	Mesulam et al., 2008; Nestor et al., 2007). However, there is not a direct correspondence
97	between atrophy or pathology and PPA subtype; thus, further work is warranted to better
98	understand how disease mechanisms might differ between the PPA subtypes.
99	Magnetic resonance spectroscopy (MRS) permits measurement of brain chemicals in
100	vivo in humans using an MRI scanner and thus can provide insight into potential disease
101	mechanisms and drug targets, distinct from conclusions that can be drawn from the atrophy and
102	pathology measurements discussed above. Standard MRS acquisitions, including short-echo
103	time (TE) Point RESolved Spectroscopy (PRESS), measure metabolites including total N-acetyl
104	aspartate (tNAA), total choline (tCho), total creatine (tCr), and glutamate+glutamine (Glx)
105	(Bottomley, 1982). tNAA, a composite measure of NAA and NAAG (N-acetylaspartylglutamate),
106	is a neuronal marker, suggested as an indicator of neuronal density and integrity (Rae, 2014).
107	tCho, the composite of phospholipid precursors phosphocholine (PCh) and
108	glycerophosphocholine (GPC), can reflect changes in membrane turnover or cell density
109	(Cleeland et al., 2019). Creatine and phosphocreatine (reported in combination as tCr) are
110	involved in brain energy metabolism and homeostasis (Rae, 2014). Glx is a combination of two
111	signals: glutamate (i.e., the principal excitatory neurotransmitter in the central nervous system)
112	and glutamine (i.e., a precursor for glutamate). J-difference editing of the spectrum using
113	MEscher-GArwood Point RESolved Spectroscopy (MEGA-PRESS) (Choi et al., 2021; Harris et
114	al., 2017; Mescher et al., 1998) allows us to quantify additional metabolites with coupled spin

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

6

systems and overlapped signals. These include the primary inhibitory neurotransmitter withinthe central nervous system, gamma-aminobutyric acid (GABA).

117 A majority of studies suggest that brain tNAA, GIx (or glutamate), and GABA levels 118 decrease with normal aging (Chiu et al., 2014; Cleeland et al., 2019; Gao et al., 2013; Haga et 119 al., 2009), and are decreased in mild cognitive impairment (MCI) (Oeltzschner et al., 2019; 120 Zeydan et al., 2017) and AD (Bai et al., 2015; Rupsingh et al., 2011; Wang et al., 2015; Zhang 121 et al., 2014) compared with normal aging. Both tCho and tCr either increase or show no change 122 with normal aging (Chiu et al., 2014; Cleeland et al., 2019; Haga et al., 2009), and are either 123 elevated (Huang et al., 2001; Marjańska et al., 2019) or not different (Marjańska et al., 2019; 124 Wang et al., 2015) in MCI and AD compared with normal aging. Functionally, lower MRS-125 measured tNAA, Glx (or glutamate), and GABA, and higher tCho, have each been associated 126 with poorer cognitive performance in normal aging (Erickson et al., 2012; Gomar et al., 2014; 127 Kantarci et al., 2011; Porges et al., 2017a; Ross et al., 2005), MCI (Griffith et al., 2007; Lim et 128 al., 2012; Oeltzschner et al., 2019; Riese et al., 2015), AD (Lim et al., 2012), and frontotemporal 129 lobar degeneration patients (Murley et al., 2022). Taken together, it is plausible that these 130 metabolites might differ between the three PPA subtypes and associate with disease severity. 131 We previously identified GABA changes in the left inferior frontal gyrus (IFG) following 132 transcranial direct current stimulation (tDCS) combined with language therapy in PPA patients 133 (Harris et al., 2019). However, the sample size included in this prior work (n = 22) was not 134 sufficient to stratify metabolite levels by the three PPA subtypes. Therefore, the objectives of the 135 present study included: 1) to characterize differences in brain metabolite levels between the 136 three PPA subtypes and determine if brain metabolite levels can discriminate between PPA 137 subtypes; and 2) to examine relationships between brain metabolite levels and PPA symptom 138 severity, as indicated by the FrontoTemporal Dementia Clinical Dementia Rating Scale (FTD-139 CDR, a measure of overall disease severity, including language function, memory, attention, 140 and independence, with scores ranging from 0 (no impairment) to 24 (severe impairment)

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

7

141	(Knopman et al., 2008)). We measured MRS metabolites in the left IFG and right sensorimotor
142	cortex (SMC). We selected the left IFG due to its involvement in several language functions
143	such as lexical selection and production, as well as other cognitive functions (Liakakis et al.,
144	2011), evident atrophy in PPA (particularly IvPPA and nfvPPA but also svPPA) (Preiß et al.,
145	2019; Rogalski et al., 2011), and response to tDCS therapy across PPA subtypes (Harris et al.,
146	2019; Tsapkini et al., 2018, 2014). We selected the right SMC (which is involved in sensory
147	processing and motor execution) as a control region. That is, we predicted that brain metabolite
148	levels would differ between PPA subtypes and associate with FTD-CDR scores for the left IFG
149	but not the right SMC.
150	
151	2. Methods

152 2.1 Participants

153 Prior to study enrollment, all patients were evaluated using neurological examination, 154 cognitive and language testing, and neuroimaging. All patients enrolled in the study were 155 diagnosed with PPA using current consensus criteria (Gorno-Tempini et al., 2011); diagnoses 156 were confirmed by expert clinicians. Additional inclusion criteria included: at least a 12th grade 157 education, right-handedness, and English as a first language. Participants were excluded if: 158 they were over 90 years of age, were not pre-morbidly proficient spellers, had progressed to 159 advanced stages of PPA or other dementia, had any diagnosed comorbid neurologic conditions 160 (e.g., stroke, psychiatric, or developmental disorder), or if they had any contraindications for 161 MRI scanning. The Johns Hopkins University Institutional Review Board (#NA 00071337) 162 approved all study procedures, and the trial was registered on ClinicalTrials.gov 163 (NCT02606422). All participants scored >0 on the FTD-CDR scale, indicating at least some 164 level of impairment to daily functioning. All participants also completed the Boston Naming Test 165 (BNT) (Kaplan et al., 2001), Hopkins Assessment on Naming Actions (HANA) (Breining et al., 166 2015), digit span (forward and backward), Letter Verbal Fluency Test (FAS), Semantic Verbal

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

8

167 Fluency Test (fruits, animals, and vegetables), and the Trail Making Test A and B (Tombaugh,

168 1999). Of note, the present work included only PPA patients and not age-matched controls; we

169 expand on the limitations of this study design in the Discussion.

170 2.2 MRS Acquisition

All MRS data were collected using the same 3.0 Tesla Philips Achieva MRI scanner 171 172 using a 32-channel head coil. For voxel positioning and tissue segmentation, we first collected a 173 whole-brain T_1 -weighted structural MRI scan, using the following parameters: magnetization-174 prepared rapid gradient-echo (MPRAGE) sequence, TR/TE = 8 ms/3.75 ms, flip angle = 8° , slice thickness = 1.0 mm, 150 slices, voxel size = 1 mm^3 isotropic voxels. Next, immediately 175 after the T_1 , we acquired metabolite spectra from two 30 x 30 x 30 mm³ voxels (Figure 1) using 176 177 both short-TE PRESS and MEGA-PRESS sequences. We positioned the left IFG voxel using 178 the anatomical landmarks of the lateral ventricles and insula. We positioned the right SMC voxel 179 by centering the voxel on the hand knob in the precentral gyrus. Both voxels were carefully 180 shifted and rotated to avoid the edge of the brain and ventricles as much as possible to avoid 181 lipid contamination and partial-volume effects.

182 To measure tNAA, tCho, tCr, and Glx, we used a standard short-TE PRESS acquisition 183 with the following parameters: TR/TE = 2000 ms/32 ms; 48 averages sampled at 2000 Hz with 184 2048 points; and water suppression using the VAPOR method (Tkáč et al., 1999). To resolve 185 GABA, we used MEGA-PRESS (Harris et al., 2017; Mescher et al., 1998) with the following 186 parameters: TR/TE = 2000 ms/68 ms; 14-ms editing pulses at 1.9 ppm and 7.46 ppm, 187 alternating every 2 averages; 320 averages in total; and VAPOR water suppression (Tkáč et al., 188 1999). MEGA-PRESS editing schemes for the detection of GABA co-edits homocarnosine and 189 macromolecular signals (Harris et al., 2015a); therefore, as is standard practice, we refer to the 190 edited 3 ppm GABA signal as GABA+ in the remainder of the manuscript. For both the short-TE 191 PRESS and MEGA-PRESS acquisitions, we also collected 8 water reference spectra without

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

192 water suppression or pre-inversion, for later use in eddy current correction and metabolite

193 quantification.



Figure 1. Voxel Placement and Spectra. (A-B) *In vivo* MR spectra were acquired from the left inferior frontal gyrus (IFG) and right sensorimotor cortex (SMC); each participant's native space binary voxel mask is normalized to standard (MNI) space and overlaid onto the spm152 template. Warmer colors indicate areas of greater overlap between participants (color bar = number of subjects overlapped). (C-D) Average short-TE PRESS and GABA-edited MEGA-PRESS spectra (black), 95% confidence interval (gray shading) and model fits (blue) for all participants for both voxels. The PRESS spectra are shown from 0.2-4.2 ppm. The MEGA-PRESS spectra are shown from 2.7-4.2 ppm.

203 2.3 MRS Data Processing

204 MRS data were analyzed using the open-source analysis toolbox Osprey (v2.0.0;

- 205 https://github.com/schorschinho/osprey/) (Oeltzschner et al., 2020) within MATLAB R2021b.
- 206 The analysis procedures followed consensus-recommended processing guidelines for PRESS
- and MEGA-PRESS data (Choi et al., 2021; Wilson et al., 2019) and match those applied in our
- 208 previous work (Zöllner et al., 2022, 2021). Briefly, for the short-TE PRESS data, analysis steps
- included: loading the vendor-native raw data (which had already been coil-combined, eddy-

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

10

210 current-corrected, and averaged on the scanner at the time of data collection), removing the residual water signal using a Hankel singular value decomposition (HSVD) filter (Barkhuijsen et 211 212 al., 1987), and modeling the metabolite peaks as described in detail in (Oeltzschner et al., 2020; 213 Zöllner et al., 2021) using a custom basis set generated by our new MRSCloud tool (https://braingps.anatomyworks.org/mrs-cloud; (Hui et al., 2022)). The basis set was generated 214 215 using PRESS localization at TE = 32 ms with the Philips-specific sequence timing and real RF 216 pulse waveforms, and consisted of simulations of 32 metabolites including NAA and NAAG 217 (=tNAA), Cr and PCr (=tCr), GPC and PCh (=tCho), Glu and Gln (=Glx), and GABA (which are 218 of interest in this study), as well as 23 other low-concentration metabolites. We then created a 219 binary mask of the two MRS voxels in subject space, co-registered these masks to each 220 participant's T_1 -weighted structural scan, and segmented the structural scans using SPM12 221 (Ashburner et al., 2014), and quantified metabolite levels with respect to the unsuppressed 222 water scan. These tissue volume fractions in the MRS voxels were used for full tissue- and 223 relaxation-corrected metabolite quantification (see below).

224 For the GABA-edited MEGA-PRESS data additional, standardized analysis steps in 225 Osprey included: eddy-current correction based on the water reference (Klose, 1990), robust 226 spectral registration (Mikkelsen et al., 2020) to separately align the individual transients within 227 each sub-spectrum, and final alignment of the averaged sub-spectra by minimizing the choline 228 peak in the difference spectrum before generating the final GABA-edited difference spectrum. 229 The co-edited macromolecules (MMs) at 3 ppm were modelled with the "1to1GABA" model, 230 which uses one composite GABA + MM basis function (i.e., the sum of the GABA and MM_{3co} 231 basis functions, with a fixed 1:1 amplitude ratio); this model assumes 50% of the 3-ppm signal in 232 the GABA-edited difference spectrum can be attributed to co-edited MMs (Deelchand et al., 233 2021; Zöllner et al., 2022). As is standard for 3 T GABA-edited MEGA-PRESS data, we considered the composite edited 3-ppm signal, i.e., "GABA+" (GABA+MM) values in our 234 235 statistical analyses.

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

11

236 Finally, we corrected all metabolite estimates in order to assess metabolite levels only in the tissue present in the voxel, which is particularly relevant for aging and neurodegenerative 237 238 disease populations who may have substantial cortical atrophy (Maes et al., 2018; Porges et al., 239 2017b). We applied tissue and relaxation correction to the short-TE PRESS values; this adjusts 240 metabolite estimates to account for atrophy and heterogeneous tissue composition within the 241 voxels, using literature values (Wansapura et al., 1999) to account for differences in water 242 visibility and relaxation times between tissue types (Gasparovic et al., 2006; Harris et al., 243 2015b). Similarly, to account for the effects of atrophy and tissue-specific water visibility and 244 relaxation, (and assuming that GABA+ levels in gray matter are twice that in white matter), we 245 applied the "alpha" correction to all GABA+ values (Harris et al., 2015b). For further details on 246 MRS data acquisition, processing, and quality, see Appendices A-B, in which we list all 247 consensus-recommended parameters (Lin et al., 2021). For further information on metabolite 248 quantification and the applied tissue correction, see Appendix C.

249 2.4 Statistical Analyses

250 We conducted all statistical analyses using R 4.0.0 (R Core Team, 2021) within RStudio 251 (RStudio Team, 2021). First, we used one-way ANOVAs (or Kruskal-Wallis non-parametric tests 252 if the ANOVA assumptions of normality and heteroskedasticity were not met) to test for group 253 differences in demographic variables, symptom severity, cognitive function, and MRS data 254 quality between the three subtypes. Next, we used linear mixed models (Ime, (Pinheiro and 255 Bates, 2000)) to examine whether metabolite levels differed by PPA subtype or brain region. In 256 the final model, we entered the metabolite level as the outcome variable, PPA subtype and 257 voxel (i.e., IFG or SMC) as predictors, and included a random intercept for each subject (similar 258 to our previous work, (Hupfeld et al., 2021)). Including the PPA subtype*voxel interaction term 259 or a random slope for each subject did not improve model fit (likelihood ratio test p > 0.05), so 260 these terms were omitted from the final statistical models. Including age or years since 261 diagnosis as additional predictors in follow-up models did not influence the statistical

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

12

262 significance of any results. Each final model satisfied the linear mixed model assumptions of 263 homogeneity of variances and normality of residuals. We used this same linear mixed model 264 approach to test for PPA subtype and brain region differences in bulk tissue composition (i.e., 265 voxel gray matter, white matter, and cerebrospinal fluid fractions). We conducted a follow-up 266 analysis using two binary logistic regressions to determine whether tCr levels significantly 267 predicted diagnosis (i.e., IvPPA vs. svPPA and IvPPA vs. nfvPPA). Including age or years since 268 diagnosis in these logistic regression models resulted in poorer model fit (higher AIC and BIC) 269 and thus these two predictors were excluded from the final model.

270 Lastly, we applied a linear model to test for relationships between brain metabolite levels 271 and PPA symptom severity (i.e., FTD-CDR scores). Given the subgroup sizes and the missing 272 MRS and FTD-CDR data (see Table B2), we conducted this analysis across the whole cohort 273 instead of stratified by PPA subtype. In addition, given the amount of missing GABA+ data 274 compared with the other metabolites (Table B2), we did not include GABA+ as a predictor in this 275 metabolite-symptom severity model (though we did test for GABA+ differences between PPA 276 subtypes, as described above). Thus, in the full model, we entered as predictors: the metabolite 277 levels from both voxels (4 metabolites/voxel), age, sex, and years since diagnosis. We then 278 selected a final model using bestalm with cross-validation, delete-d method, and 1,000 279 replications to produce a final model that retained only the best predictors of FTD-CDR score 280 (McLeod and Xu, 2010; Zhang, 2016). The FTD-CDR scores were not normally distributed 281 (Shapiro test p < 0.05), so we reran the same model selection procedure after square root-282 transforming the FTD-CDR variable, which improved the normality of the data (Shapiro test p > p283 0.05).

284

285 286

287

288

289

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

13

290 3. Results

291 **3.1 Sample Characteristics**

292 The total cohort consisted of 61 PPA patients: 22 IvPPA, 27 nfvPPA, and 12 svPPA. 293 There were no differences in sex, age, time since diagnosis, or symptom severity based on PPA 294 subtype (Table 1). As anticipated (Beales et al., 2019; Gorno-Tempini et al., 2004; Wicklund et 295 al., 2014), svPPA participants performed worst on the tests of naming (i.e., BNT and HANA) and 296 semantic verbal fluency (Fruits, Animals Vegetables), and IvPPA participants performed worst 297 on the Digit Span – Forward and Backward tasks, which assess verbal working memory (Table 298 1). There were no subtype differences for the remaining cognitive tasks (i.e., FAS or Trail 299 Making – A and B tests; Table 1). IFG short-TE PRESS data was not collected for 2 300 participants, IFG MEGA-PRESS data was not collected for 1 participant, and FTD-CDR scores 301 were missing for 7 participants. Table B2 details additional data omissions from statistical 302 analyses; MRS data were excluded if NAA linewidth was greater than 15 Hz (Cao et al., 2018; 303 Deelchand et al., 2021; Mosser and Edwards, 2008; Nwaroh et al., 2020; Sasaki et al., 2021) or 304 if incorrect pulse sequence parameters were used during acquisition. Group mean spectra (after 305 these exclusions) are presented in Figure 1, and spectra for a single exemplar participant are 306 shown in Figure B1. Data quality metrics (i.e., linewidth, SNR, fit error, and drift) are presented 307 for the whole cohort (Appendix A) and by PPA subtype (Appendix B). There were no differences 308 in MRS data quality based on PPA subtype (Table B1).

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

Table 1. Sample Characteristics

	IvPPA	nfvPPA	svPPA	F or χ ²	р	η²
n	22	27	12			
Sex	13 F; 9 M	11 F; 16 M	7 F; 5 M	1.97	0.373	
Age (years)	65.55 (8.12)	68.59 (6.62)	68.67 (5.25)	1.36	0.265	0.04
Years of education ^{a,b}	16.48 (1.91)	16.83 (2.44)	16.35 (2.33)	0.23	0.799	0.01
Years since diagnosis ^{a,c}	3.93 (2.83)	3.81 (2.58)	5.05 (2.91)	0.83	0.442	0.03
FTD-CDR sum score ^{a,d}	6.55 (5.17)	5.26 (4.17)	7.61 (5.59)	0.87	0.424	0.03
Boston Naming Test (BNT) ^{a,e}	19.19 (9.03)	22.00 (8.09)	4.00 (3.95)	20.68	< 0.001***	0.43
Hopkins Assessment on Naming Actions (HANA) ^{a,f}	20.90 (9.72)	24.28 (9.62)	9.10 (6.74)	9.72	< 0.001***	0.27
Letter Verbal Fluency (FAS) ^{a,h}	18.77 (12.38)	16.58 (10.22)	21.90 (15.44)	0.73	0.487	0.03
Semantic Verbal Fluency (Fruits, Animals, Vegetables) ^h	20.73 (13.48)	22.00 (12.75)	10.10 (7.40)	3.55	0.036*	0.11
Digit Span – Forward ^g	3.82 (1.82)	4.58 (1.64)	6.35 (1.76)	7.36	0.001**	0.21
Digit Span – Backward ^g	2.36 (1.15)	2.96 (1.24)	4.80 (1.70)	12.29	< 0.001***	0.31
Trail Making Test - Aa,i	98.18 (97.26)	53.96 (21.14)	47.89 (17.90)	3.14	0.053	0.12
Trail Making Test - B ^{a,i}	233.12 (85.03)	196.11 (89.90)	147.89 (96.74)	2.71	0.078	0.11

Table 1 Note. For each metric, we report the mean (standard deviation) for each PPA subtype. We also report the results of one-way ANOVAs to characterize differences in each variable between the subtype groups. For sex, we report the number of males (M) and females (F) and the result of a Pearson's chi-square test for differences in the sex distribution within each group. This table includes all available participants; however, statistical analyses of MRS data omitted several additional participants (see Table B2). *p < 0.05, **p < 0.01, ***p < 0.001.

^a In cases where the variable did not meet the one-way ANOVA assumptions of homogeneity of variances between groups, independence of residuals, and/or normality of residuals (indicated by the subscript 'a'), we reran each analysis using the non-parametric Kruskal-Wallis test. In all cases, the non-parametric test did not change the statistical significance of the result.

- ^b Years of education was unavailable for 1 IvPPA, 3 nfvPPA, and 2 svPPA patients.
- ^c Years since diagnosis was unavailable for 1 lvPPA, 3 nfvPPA, and 1 svPPA patients.
- ^d FTD-CDR sum score was unavailable for 4 nfvPPA patients and 3 svPPA patients.
- ^e BNT was scored out of 30 possible points. BNT score was unavailable for 1 lvPPA, 2 nfvPPA, and 1 svPPA patient.
- ^f HANA was scored out of 35 possible points. HANA score was unavailable for 1 lvPPA, 2 nfvPPA, and 2 svPPA patients.
- ⁹ Digit Span Forward and Backward were scored out of 9 possible points each. Digit span scores were unavailable for 1 nfvPPA patient and 2 svPPA patients.
- ^h FAS and Fruits, Animals, Vegetables were scored as the number of words the participant could name starting with
 the letters F, A, and S or in each fruit/animal/vegetable category (1 minute for each trial). These scores were
 unavailable for 1 nfvPPA patient and 2 svPPA patients.
- ⁱ Trail Making Test A and B scores are in seconds required to complete the task. Trail Making Test B was
 terminated after 300 seconds. Trail Making Test scores were unavailable for 5 lvPPA, 6 nfvPPA, and 3 svPPA
 patients.
- 345 **3.2 Differences in Brain Metabolite Levels by PPA Subtype**
- 346 tCr levels differed by subtype across both voxels; svPPA patients had higher mean tCr
- 347 compared with lvPPA patients (p = 0.019; Figure 2; Table 2). nfvPPA patients had higher mean

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

15

348	tCr levels compared with IvPPA patients, though this difference did not reach statistical
349	significance within the linear mixed effects model ($p = 0.071$; Figure 2; Table 2). Including age in
350	this model did not change the statistical significance of any results (svPPA vs. lvPPA: $p = 0.045$;
351	nfvPPA vs. lvPPA: $p = 0.175$). However, age was also a significant predictor of tCr levels; older
352	age was associated with greater tCr levels ($p = 0.011$). There were no other differences in brain
353	metabolite levels (all $p > 0.05$; Figure 2; Table 2) or voxel tissue fractions (all $p > 0.05$; Table
354	B4) based on PPA subtype. Moreover, there were no associations between years since
355	diagnosis and any metabolite levels (all $p > 0.05$).
356	Comparing IvPPA and svPPA, the follow-up binary logistic regression model revealed a
357	statistically significant association between diagnosis and tCr levels (odds ratio: 3.08; 95%
358	confidence interval: 1.46-7.21; $p = 0.005$). Comparing IvPPA and nfvPPA, the association
359	between diagnosis and tCr levels was not statistically significant (odds ratio: 1.72; 95%
360	confidence interval: 1.00-3.12; $p = 0.062$). Including age and years since diagnosis in these
361	models did not improve model fit (higher AIC and BIC), and these predictors were not
362	statistically significant indicators of PPA subtype ($p > 0.05$ in all cases).
363	3.3 Regional Differences in Brain Metabolites and Voxel Composition
364	tNAA was lower in the IFG compared with the SMC ($p < 0.001$), while tCho, tCr, and Glx
365	were higher in the IFG compared with the SMC (all $p < 0.001$; Figure 2; Table 2). GABA+ did
366	not differ by brain region ($p = 0.626$; Figure 2; Table 2). The IFG compared with the SMC voxel
367	had a higher gray matter ($p < 0.001$) and lower white matter fraction ($p < 0.001$), as well as a

368 greater total tissue fraction (i.e., higher gray matter + white matter fraction; p = 0.012; Table B4).

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA



Figure 2. Differences in Metabolites by PPA Subtype and Brain Region. Metabolite levels for the IvPPA (pink),

nfvPPA (green), and svPPA (blue) subtypes are shown for the IFG (left) and SMC (right) voxels.

 $\frac{373}{100}$ * indicates p < 0.05 for the comparison of svPPA tCr levels with lvPPA tCr levels.

374 *** indicates p < 0.001 for the comparison of metabolite values within the SMC versus the IFG.

Table 2. Differences in Metabolites by PPA Subtype and Brain Region

Predictors	Estimates (SE)	CI	t	р
tNAA (i.u.)	· · ·			-
Diagnosis (nfvPPA)	-0.53 (0.33)	-1.19-0.12	-1.60	0.115
Diagnosis <i>(svPPA)</i>	-0.17 (0.41)	-0.98-0.64	-0.41	0.684
Voxel (SMC)	2.58 (0.19)	2.20-2.95	13.44	< 0.001***
tCho (i.u.)				
Diagnosis <i>(nfvPPA)</i>	0.11 (0.09)	-0.07-0.28	1.22	0.227
Diagnosis <i>(svPPA)</i>	-0.12 (0.11)	-0.34-0.09	-1.12	0.269
Voxel (SMC)	-0.26 (0.05)	-0.35-(-0.16)	-5.38	< 0.001***
tCr (i.u.)				
Diagnosis <i>(nfvPPA)</i>	0.34 (0.18)	-0.02-0.69	1.84	0.071
Diagnosis <i>(svPPA)</i>	0.54 (0.23)	0.10-0.99	2.40	0.019*
Voxel (SMC)	-0.40 (0.11)	-0.61-(-0.19)	-3.78	< 0.001***
Glx (i.u.)				
Diagnosis <i>(nfvPPA)</i>	0.91 (0.60)	-0.27-2.09	1.51	0.136
Diagnosis <i>(svPPA)</i>	0.01 (0.74)	-1.45-1.47	0.01	0.988
Voxel (SMC)	-2.58 (0.33)	-3.23-(-1.93)	-7.79	< 0.001***
GABA+ (i.u.)				
Diagnosis <i>(nfvPPA)</i>	-0.10 (0.28)	-0.65-0.45	-0.37	0.716
Diagnosis <i>(svPPA)</i>	0.10 (0.36)	-0.60-0.80	0.28	0.782
Voxel (SMC)	-0.11 (0.23)	-0.57-0.34	-0.49	0.626

378

368

371

375 376 377

Table 2 Note. Here we report the results of a linear mixed effects model testing for PPA subtype and voxel

differences in each metabolite. IvPPA and IFG served as the reference groups. For ease of interpretation, in this table
 we included only the predictors of interest; see Table B3 for all model and fit information. SE = standard error; CI =

382 95% confidence interval. p < 0.05, p < 0.001.

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

17

383

384 3.4 Metabolite Relationships with PPA Symptom Severity

385 We included all short-TE PRESS metabolite levels from both voxels (i.e., 4 386 measures/voxel), age, sex, PPA subtype, and years since diagnosis in the full statistical model. 387 and only those participants without missing short-TE PRESS or FTD-CDR data (n = 49; see 388 Table B2). The final model retained left IFG tCr, left IFG GIx, and years since diagnosis as 389 statistically significant predictors of FTD-CDR score (Table 3). That is, across the whole cohort, 390 worse PPA symptoms (i.e., higher FTD-CDR scores) were associated with higher left IFG tCr 391 levels (partial r = 0.39; p = 0.007; Figure 3), lower left IFG Glx levels (partial r = -0.36; p = 0.012; 392 Figure 3), and longer disease duration (partial r = 0.34; p = 0.021). Rerunning this model with 393 the square root of FTD-CDR scores as the outcome variable (to meet the normality assumption) 394 returned the same three predictors and did not change the statistical significance of any results. 395 Requiring that age and PPA subtype be included in the model did not change the statistical 396 significance of the metabolite or disease duration predictors, and neither age (p = 0.529) nor 397 PPA subtype (nfvPPA vs. lvPPA: p = 0.224; svPPA vs. lvPPA: p = 0.483) were significant 398 predictors of FTD-CDR score.



BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

18

Figure 3. Relationship of IFG tCr and Glx with FTD-CDR Score. This figure depicts the partial correlations of tCr and Glx levels in the left IFG with FTD-CDR scores across all participants (IVPPA = pink, nfvPPA = green, svPPA =blue). These partial correlations account for the effects of the other predictors included in the final statistical model on the variable of interest (i.e., tCr values are corrected for Glx and years since diagnosis, and Glx values are corrected for tCr and years since diagnosis). Higher FTD-CDR scores indicate worse PPA symptom severity. These plots include *n* = 49 individuals, after exclusion of missing and unusable data (see Table B2).

Table 3. Metabolites Relationships with PPA Symptom Severity

Predictors	Estimates (SE)	CI	t	р	R ² / R ² Adjusted
(Intercept)	-14.18 (9.19)	-32.69-4.32	-1.54	0.130	
IFG tCr (i.u.)	1.96 (0.69)	0.57-3.35	2.84	0.007**	
IFG Glx (i.u.)	-0.55 (0.21)	-0.98-(-0.13)	-2.61	0.012*	
Years since diagnosis	0.48 (0.20)	0.08-0.89	2.39	0.021*	
0					0.34 / 0.29

409

410 *Table 3 Note.* Here we report the results of the final linear model testing for associations between brain metabolite 411 levels and FTD-CDR (i.e., PPA symptom severity) scores. SE = standard error; CI = 95% confidence interval. 412 *p < 0.05, **p < 0.01.

413 414

415 4. Discussion

416	This is the first study to investigate brain metabolite differences between PPA subtypes
417	using MRS. Our key findings included, firstly, that tissue-corrected tCr differed by PPA subtype
418	across the left IFG and right SMC; IvPPA patients had the lowest tCr levels, followed by nfvPPA,
419	and svPPA patients with the highest brain tCr levels. Moreover, tCr levels significantly
420	differentiated between IvPPA and svPPA diagnosis. Secondly, higher tissue-corrected tCr and
421	lower Glx levels in the left IFG (i.e., a brain region critical for language function) were associated
422	with more severe symptoms as indicated by the FTD-CTR scale (which indexes language
423	function as well as other cognitive and daily living domains (Knopman et al., 2008)). Together,
424	these results suggest that brain tCr may play a role in PPA pathology or progression,
425	particularly for the svPPA subtype, and could have utility for differentiating svPPA from other
426	PPA subtypes. Both tCr and GIx might be explored as biomarkers for tracking disease severity
427	and progression.
428	4.1 Higher tCr Levels in svPPA
429	Those with svPPA had the highest tCr levels across both the left IFG and right SMC.
430	The creatine (Cr)/phosphocreatine (PCr) system is a short-lived energetic system that allows

431 exchange of high-energy phosphate between Cr, adenosine triphosphate (ATP), and adenosine

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

19

432 diphosphate (ADP) via creatine kinase, the primary enzyme in the Cr system. The Cr/PCr 433 system simultaneously supplies a high-energy pool capable of rapidly regenerating ATP during 434 high energetic demands, while also dispersing ATP across the cell to connect ATP consumption 435 to the site of energy production (Bürklen et al., 2006). Cr is found in the highest concentrations 436 in tissues with high ATP demand, including muscle and brain tissue (Rackayova et al., 2017; 437 Rae, 2014). In the present work, we measured tCr (i.e., the sum of Cr and PCr): tCr is thus 438 reflective of the Cr/PCr system more generally, including PCr anabolism, Cr degradation, and Cr 439 extracellular transport.

440 Previous MRS studies have reported elevated tCr in normal aging (Chang et al., 1996; 441 Charlton et al., 2007; Chiu et al., 2014; Cleeland et al., 2019; Haga et al., 2009; Pfefferbaum et 442 al., 1999; Reyngoudt et al., 2012), MCI and AD (Huang et al., 2001), and other neurological 443 conditions with cognitive symptoms (e.g., HIV-positive patients with neurological symptoms 444 (Chang et al., 2003, 2002)). It remains unclear whether this is due to increased Cr and/or PCr 445 synthesis, or decreased clearance of these metabolites from the brain (Chang et al., 1996). 446 Elevated tCr in svPPA could also represent gliosis (Ratai et al., 2011; Revngoudt et al., 2012; 447 Saunders et al., 1999). tCr concentration in glial cells is about 2-4x that of neurons (Urenjak et 448 al., 1993), and prior work has found an association between higher tCr in non-human primates 449 and more severe gliosis (Ratai et al., 2011) and an association between PPA and accumulation 450 of activated microglia in both gray (Kim et al., 2016) and white matter (Ohm et al., 2019). In 451 addition, activated microglia have been reported to occur close to pathologic insults such as 452 TDP43 inclusions in PPA patients with TDP43-positive pathology (Kim et al., 2016), i.e., the 453 pathology most associated with svPPA (Gorno-Tempini et al., 2011).

It is also plausible that higher tCr in svPPA could be a compensatory response to
reduced neuronal mitochondrial trafficking (i.e., movement of new mitochondria from the soma
to distal axons (Cheng and Sheng, 2021)). Mitochondria are anchored in the cell by syntaphilin
(SNPH) (Kang et al., 2008), which is elevated in TDP43-positive frontotemporal lobar

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

20

degeneration (Andres-Benito et al., 2019), the pathology most associated with svPPA (GornoTempini et al., 2011)). Elevated SNPH in svPPA could result in decreased mitochondrial
motility, resulting in a greater need to disperse high-energy phosphate across the cell and thus
elevated neuronal Cr. In support of this, neurons lacking appropriate mitochondrial trafficking
machinery have reduced ability to form long dendrites, but this is rescued with Cr
supplementation (Fukumitsu et al., 2015). Thus, while several mechanisms may contribute to
the observed higher tCr levels in svPPA, the specific underlying cause requires further study.

465 4.2 Lower tCr Levels in lvPPA

466 It also remains unclear why tCr levels were the lowest for IvPPA patients. Though left 467 IFG atrophy is reported to be more pronounced for IvPPA compared with svPPA (Preiß et al., 468 2019), we found tCr differences by PPA subtype across both left IFG and right SMC, suggesting 469 more global tCr differences (not specific to one brain region). It is perhaps counterintuitive that 470 tCr levels were lowest for IvPPA patients, given that IvPPA is most closely associated with AD 471 pathology (Mesulam et al., 2008; Rabinovici et al., 2008) and tCr is elevated in AD compared 472 with healthy controls (Huang et al., 2001). It is possible that the reported IvPPA tCr levels are in 473 a similar range to those with AD. Though we are unaware of any studies which directly compare 474 tCr levels in AD versus (Iv)PPA patients, recent work found no differences in MRS-measured 475 NAA and mI levels between AD and PPA patients (Mitolo et al., 2021), suggesting that certain 476 brain metabolite levels might be similar between these two neurodegenerative conditions. 477 However, without AD or control groups in the present work, we are unable to make such direct 478 comparisons.

479 **4.3 No PPA Subtype Differences for Other Neurometabolites**

We identified differences in brain metabolite levels by PPA subtype only for tCr, but not for the other four investigated metabolites. The metabolite values reported here are corrected for bulk tissue concentrations (Gasparovic et al., 2006; Harris et al., 2015b); that is, we report metabolite values only within the brain tissue that remains in the voxels, accounting for age-

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

21

related atrophy of gray and white matter. Therefore, our results are not likely explained entirely by subtype differences in atrophy location and severity. Moreover, as we did not identify PPA subtype differences in tNAA levels, it is less likely that tCr subtype differences were driven only by diffuse neuronal loss. Instead, we predict that these subtype differences in tCr are more related to differences in brain energy metabolism, though this hypothesis warrants further investigation in larger cohorts which include healthy aging controls.

490 **4.4 tCr and Glx Associations with PPA Symptoms**

491 We found that both higher tCr and lower GIx levels correlated with more severe PPA 492 symptoms, as indicated by the FTD-CDR inventory. This suggests that higher brain tCr and 493 lower brain GIx levels could be (directly or indirectly) related to maladaptive disease processes. 494 These brain-behavior relationships occurred only for the left IFG but not the right SMC. The 495 regional specificity of this association is plausible (and was hypothesized), as the FTD-CDR 496 inventory includes both language and cognitive function sections; the left IFG is involved in 497 language selection and production (e.g., both oral and written naming and spelling), as well as 498 other cognitive functions (e.g., articulatory loop in working memory) (Liakakis et al., 2011), while 499 the SMC roles are mostly related to motor execution and sensory processing. Higher tCr levels 500 might indicate disruptions in underlying cellular bioenergetic processes, which could contribute 501 to the development of more severe language and other cognitive symptoms in PPA patients; 502 however, such claims warrant further replication in future studies with larger samples, as well as 503 exploration of tCr relationships with additional cognitive metrics.

504 While higher tCr correlated with more severe PPA symptoms, higher brain tCr levels 505 might not be entirely dysfunctional; the relationship between tCr and PPA disease processes 506 could be more complex. Oral Cr supplementation has been shown to improve cognitive function 507 in normal adults (Avgerinos et al., 2018) (though results differed by cognitive domain, effect 508 sizes were small to moderate, and no large-scale Cr supplementation studies have been 509 conducted in PPA patients). Moreover, multiple prior studies have reported *lower* tCr levels or

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

22

no difference in tCr levels for normal aging cohorts (Cleeland et al., 2019). While these studies
used varying methods (e.g., different MRI scanner field strengths and different brain regions), it
remains unclear what other factors might influence brain tCr changes in aging and disease.
Moreover, as we were unable to include an age-matched control group in the present study, it
could be that the tCr levels we report for the PPA patients do not differ significantly from those
of normal aging.

517 cognitive and visuomotor performance in both normal aging (Levin et al., 2019; Zahr et al.,

518 2013) and neurodegenerative disease (i.e., MCI (Oeltzschner et al., 2019; Zeydan et al., 2017)

and frontotemporal lobar degeneration (Murley et al., 2022, 2020)). Reduced Glx could indicate

520 loss of glutamatergic neurons or disturbances in glutamate and/or glutamine synthesis, which

521 could each reasonably contribute to poorer functional performance. Moreover, as glutamate is a

522 component involved in the synthesis of glutathione (i.e., one of the most abundant brain

523 antioxidants), it could also be that increased brain oxidative stress in response to disease

524 processes would result in greater glutathione production (Duffy et al., 2014; Hupfeld et al.,

525 2021), and thus lower detectable brain glutamate levels. In our cohort, tCr was not correlated

526 with Glx levels in either the IFG (Pearson r = -0.04; p = 0.782) or SMC (Pearson r = 0.13; p =

527 0.383), and thus each metabolite may distinctly contribute (directly or indirectly) to PPA disease

528 processes. Further investigation is warranted to better understand the precise mechanisms by

529 which tCr and Glx might each associate with PPA symptoms and progression.

530 **4.5 Limitations**

531 There are several limitations to this work. Our cross-sectional approach precluded us 532 from assessing how these metabolite levels may alter prior to PPA onset and with disease 533 progression. Though years since diagnosis did not differ between subtypes and was distinct 534 from the tCr and Glx relationships with symptom severity, it still could be that disease 535 progression rather than subtype more strongly influences brain metabolite levels. PPA is

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

23

relatively rare and difficult to diagnose (Knopman et al., 2008); thus, we were unable to compare 536 individuals at the same stage in their disease progression. Similarly, though age did not differ 537 538 between subtypes and was distinct from the subtype differences in tCr levels, the reported tCr 539 levels in PPA may not differ substantially from normal aging. We were unable to address this 540 question due to the lack of a normal aging control group. There were no differences in the 541 relationship between tCr and symptom severity based on PPA subtype, though all groups 542 trended in the same direction; however, we were likely underpowered to investigate any group 543 differences in this brain-behavior relationship.

544 In addition, there are several limitations to the MRS methods used. Our methods do not 545 allow us to distinguish the contribution of PCr versus Cr to the tCr signal, or the contribution of 546 glutamate versus glutamine to the Glx signal. The tissue corrections applied here are standard 547 for aging cohorts with cortical atrophy (Gasparovic et al., 2006; Harris et al., 2015b); however, 548 these corrections use literature values (Wansapura et al., 1999) for relaxation constants. 549 Changes in water and metabolite relaxation rates with aging and disease could also impact 550 metabolite guantification (Deelchand et al., 2020; Marjańska et al., 2017, 2013), though these 551 were not quantified and thus could not be incorporated into our tissue corrections. The short-TE 552 PRESS data were averaged on the scanner (instead of collecting individual spectra); therefore, 553 frequency drift correction could not be performed on the short-TE PRESS data. It is 554 recommended that future studies use post-processing drift corrections for all MRS data. PPA 555 patients often have more difficulty than others remaining still in the scanner, which could have 556 affected spectral quality (though we excluded any participants with NAA linewidth > 15 Hz); 557 moreover, ability to complete an MRI scan precluded us from enrolling any extremely advanced 558 PPA cases in this cohort.

559 **5. Conclusions**

560 We found that brain tCr differs between PPA subtypes. tCr is highest for svPPA patients, 561 and brain tCr levels differentiate svPPA from lvPPA diagnosis. We also found a correlation

- 562 between both higher left IFG tCr levels and lower left IFG Glx levels and more severe PPA
- 563 symptoms. These results suggest that tCr may be useful in differentiating between PPA
- subtypes, and that both tCr and Glx could have utility as markers of PPA symptom severity.
- 565 However, further work in larger cohorts which include a normal aging control group is needed to
- 566 better understand the potential roles of tCr and Glx in PPA development and progression.

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

25

567 Ethics Approval and Consent to Participate

- 568 The Johns Hopkins University Institutional Review Board (#NA_00071337) approved all
- study procedures, and written informed consent was obtained from all participants.
- 570 **Consent for Publication**
- 571 All authors consent to the publication of this study.

572 Availability of Data and Material

- 573 The raw data supporting the conclusions of this manuscript will be made available by the
- 574 authors without undue reservation.

575 Competing Interests

576 All authors declare that they have no competing interests.

577 Funding

- 578 This work was supported by grants from the National Institute on Aging (K00 AG068440-
- 579 03 to KH, R00 AG062230 to GO, and R01 DC014475-05 and R01 AG068881-02 to KT) and
- 580 grants from the National Institute of Biomedical Imaging and Bioengineering (R01 EB016089 to
- 581 RE, and P41 EB031771).

582 Author Contributions

583 KH analyzed the MRS data, conducted all statistical analyses, created all figures and 584 supplemental material, and wrote the first draft of the manuscript. HZ, GO, SH, AH, and RAE 585 consulted on MRS data analyses and interpretation. HH contributed to manuscript writing and 586 results interpretation. OH, JG, AH, and KT facilitated MRS and behavioral data collection. KT 587 and RAE designed the project and led interpretation and discussion of the results. All authors 588 participated in revision of the manuscript.

589 Acknowledgements

590 The authors also wish to thank all of the participants who volunteered their time, without 591 whom this project would not have been possible.

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

592 **References**

- Andres-Benito, P., Gelpi, E., Povedano, M., Ausin, K., Fernandez-Irigoyen, J., Santamaría, E.,
 Ferrer, I., 2019. Combined transcriptomics and proteomics in frontal cortex area 8 in
 frontotemporal lobar degeneration linked to C9orf72 expansion. J. Alzheimers Dis. 68,
 1287–1307.
- Ashburner, J., Barnes, G., Chen, C.-C., Daunizeau, J., Flandin, G., Friston, K., Kiebel, S.,
 Kilner, J., Litvak, V., Moran, R., 2014. SPM12 manual. Wellcome Trust Cent.
 Neuroimaging Lond. UK 2464, 4.
- Avgerinos, K.I., Spyrou, N., Bougioukas, K.I., Kapogiannis, D., 2018. Effects of creatine
 supplementation on cognitive function of healthy individuals: A systematic review of
 randomized controlled trials. Exp. Gerontol. 108, 166–173.
- Bai, X., Edden, R.A., Gao, F., Wang, G., Wu, L., Zhao, B., Wang, M., Chan, Q., Chen, W.,
 Barker, P.B., 2015. Decreased γ-aminobutyric acid levels in the parietal region of
 patients with Alzheimer's disease. J. Magn. Reson. Imaging 41, 1326–1331.
- Barkhuijsen, H., De Beer, R., Van Ormondt, D., 1987. Improved algorithm for noniterative time domain model fitting to exponentially damped magnetic resonance signals. J. Magn.
 Reson. 1969 73, 553–557.
- Beales, A., Whitworth, A., Cartwright, J., Panegyres, P.K., Kane, R.T., 2019. Profiling sentence
 repetition deficits in primary progressive aphasia and Alzheimer's disease: Error patterns
 and association with digit span. Brain Lang. 194, 1–11.
 https://doi.org/10.1016/j.bandl.2019.03.001
- 613 Bottomley, P., 1982. Selective volume method for performing localized NMR spectroscopy. 614 US4480228A.
- Breining, B., Tippett, D., Davis, C., Posner, J., Sebastian, R., Oishie, K., Hillis, A., 2015.
 Assessing dissociations of object and action naming in acute stroke, in: Clinical
 Aphasiology Conference.
- Bürklen, T.S., Schlattner, U., Homayouni, R., Gough, K., Rak, M., Szeghalmi, A., Wallimann, T.,
 2006. The creatine kinase/creatine connection to alzheimer's disease: CK Inactivation,
 APP-CK complexes and focal creatine deposits. J. Biomed. Biotechnol. 2006.
- Cao, G., Edden, R.A.E., Gao, F., Li, H., Gong, T., Chen, W., Liu, X., Wang, G., Zhao, B., 2018.
 Reduced GABA levels correlate with cognitive impairment in patients with relapsingremitting multiple sclerosis. Eur. Radiol. 28, 1140–1148. https://doi.org/10.1007/s00330017-5064-9
- 625 Chang, L., Ernst, T., Poland, R.E., Jenden, D.J., 1996. In vivo proton magnetic resonance 626 spectroscopy of the normal aging human brain. Life Sci. 58, 2049–2056.
- Chang, L., Ernst, T., Witt, M.D., Ames, N., Gaiefsky, M., Miller, E., 2002. Relationships among
 brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients.
 Neuroimage 17, 1638–1648.
- Chang, L., Ernst, T., Witt, M.D., Ames, N., Walot, I., Jovicich, J., DeSilva, M., Trivedi, N., Speck,
 O., Miller, E.N., 2003. Persistent brain abnormalities in antiretroviral-naive HIV patients 3
 months after HAART. Antivir. Ther. 8, 17–26.
- Charlton, R.A., McIntyre, D.J.O., Howe, F.A., Morris, R.G., Markus, H.S., 2007. The relationship
 between white matter brain metabolites and cognition in normal aging: the GENIE study.
 Brain Res. 1164, 108–116.
- Cheng, X.-T., Sheng, Z.-H., 2021. Developmental regulation of microtubule-based trafficking
 and anchoring of axonal mitochondria in health and diseases. Dev. Neurobiol. 81, 284–
 299.
- Chiu, P.-W., Mak, H.K.-F., Yau, K.K.-W., Chan, Q., Chang, R.C.-C., Chu, L.-W., 2014. Metabolic
 changes in the anterior and posterior cingulate cortices of the normal aging brain: proton
 magnetic resonance spectroscopy study at 3 T. Age 36, 251–264.

- Choi, I.-Y., Andronesi, O.C., Barker, P., Bogner, W., Edden, R.A., Kaiser, L.G., Lee, P.,
 Marjańska, M., Terpstra, M., de Graaf, R.A., 2021. Spectral editing in 1H magnetic
 resonance spectroscopy: Experts' consensus recommendations. NMR Biomed. 34,
 e4411.
- 646 Cleeland, C., Pipingas, A., Scholey, A., White, D., 2019. Neurochemical changes in the aging
 647 brain: A systematic review. Neurosci. Biobehav. Rev. 98, 306–319.
- Cotelli, M., Manenti, R., Ferrari, C., Gobbi, E., Macis, A., Cappa, S.F., 2020. Effectiveness of
 language training and non-invasive brain stimulation on oral and written naming
 performance in Primary Progressive Aphasia: A meta-analysis and systematic review.
 Neurosci. Biobehav. Rev. 108, 498–525.
- Davies, R.R., Hodges, J.R., Kril, J.J., Patterson, K., Halliday, G.M., Xuereb, J.H., 2005. The
 pathological basis of semantic dementia. Brain 128, 1984–1995.
- Deelchand, D.K., Marjańska, M., Henry, P.-G., Terpstra, M., 2021. MEGA-PRESS of GABA+:
 influences of acquisition parameters. NMR Biomed. 34, e4199.
- Deelchand, D.K., McCarten, J.R., Hemmy, L.S., Auerbach, E.J., Eberly, L.E., Marjańska, M.,
 2020. Changes in the intracellular microenvironment in the aging human brain.
 Neurobiol. Aging 95, 168–175.
- Duffy, S.L., Lagopoulos, J., Hickie, I.B., Diamond, K., Graeber, M.B., Lewis, S.J., Naismith, S.L.,
 2014. Glutathione relates to neuropsychological functioning in mild cognitive impairment.
 Alzheimers Dement. 10, 67–75.
- Erickson, K.I., Weinstein, A.M., Sutton, B.P., Prakash, R.S., Voss, M.W., Chaddock, L., Szabo,
 A.N., Mailey, E.L., White, S.M., Wojcicki, T.R., 2012. Beyond vascularization: aerobic
 fitness is associated with N-acetylaspartate and working memory. Brain Behav. 2, 32–
 41.
- Fukumitsu, K., Fujishima, K., Yoshimura, A., Wu, Y.K., Heuser, J., Kengaku, M., 2015.
 Synergistic action of dendritic mitochondria and creatine kinase maintains ATP
 homeostasis and actin dynamics in growing neuronal dendrites. J. Neurosci. 35, 5707–
 5723.
- Gao, F., Edden, R.A., Li, M., Puts, N.A., Wang, G., Liu, C., Zhao, B., Wang, H., Bai, X., Zhao,
 C., 2013. Edited magnetic resonance spectroscopy detects an age-related decline in
 brain GABA levels. Neuroimage 78, 75–82.
- Gasparovic, C., Song, T., Devier, D., Bockholt, H.J., Caprihan, A., Mullins, P.G., Posse, S.,
 Jung, R.E., Morrison, L.A., 2006. Use of tissue water as a concentration reference for
 proton spectroscopic imaging. Magn. Reson. Med. Off. J. Int. Soc. Magn. Reson. Med.
 55, 1219–1226.
- Gomar, J.J., Gordon, M.L., Dickinson, D., Kingsley, P.B., Uluğ, A.M., Keehlisen, L., Huet, S.,
 Buthorn, J.J., Koppel, J., Christen, E., 2014. APOE genotype modulates proton magnetic
 resonance spectroscopy metabolites in the aging brain. Biol. Psychiatry 75, 686–692.
- Gorno-Tempini, M.L., Dronkers, N.F., Rankin, K.P., Ogar, J.M., Phengrasamy, L., Rosen, H.J.,
 Johnson, J.K., Weiner, M.W., Miller, B.L., 2004. Cognition and anatomy in three variants
 of primary progressive aphasia. Ann. Neurol. 55, 335–346.
 https://doi.org/10.1002/ana.10825
- Gorno-Tempini, M.L., Hillis, A.E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S.F., Ogar,
 J.M., Rohrer, J.D., Black, S., Boeve, B.F., 2011. Classification of primary progressive
 aphasia and its variants. Neurology 76, 1006–1014.
- Griffith, H.R., den Hollander, J.A., Okonkwo, O., Evanochko, W.T., Harrell, L.E., Zamrini, E.Y.,
 Brockington, J.C., Marson, D.C., 2007. Executive function is associated with brain proton
 magnetic resonance spectroscopy in amnestic mild cognitive impairment. J. Clin. Exp.
 Neuropsychol. 29, 599–609.
- Grossman, M., 2010. Primary progressive aphasia: clinicopathological correlations. Nat. Rev.
 Neurol. 6, 88–97.

- Haga, K.K., Khor, Y.P., Farrall, A., Wardlaw, J.M., 2009. A systematic review of brain metabolite
 changes, measured with 1H magnetic resonance spectroscopy, in healthy aging.
 Neurobiol. Aging 30, 353–363.
- Harris, A.D., Puts, N.A., Barker, P.B., Edden, R.A., 2015a. Spectral-editing measurements of
 GABA in the human brain with and without macromolecule suppression. Magn. Reson.
 Med. 74, 1523–1529.
- Harris, A.D., Puts, N.A., Edden, R.A., 2015b. Tissue correction for GABA-edited MRS:
 Considerations of voxel composition, tissue segmentation, and tissue relaxations. J.
 Magn. Reson. Imaging 42, 1431–1440.
- Harris, A.D., Saleh, M.G., Edden, R.A., 2017. Edited 1H magnetic resonance spectroscopy in vivo: Methods and metabolites. Magn. Reson. Med. 77, 1377–1389.
- Harris, A.D., Wang, Z., Ficek, B., Webster, K., Edden, R.A., Tsapkini, K., 2019. Reductions in
 GABA following a tDCS-language intervention for primary progressive aphasia.
 Neurobiol. Aging 79, 75–82.
- Hodges, J.R., Davies, R.R., Xuereb, J.H., Casey, B., Broe, M., Bak, T.H., Kril, J.J., Halliday,
 G.M., 2004. Clinicopathological correlates in frontotemporal dementia. Ann. Neurol. 56,
 399–406.
- Huang, W., Alexander, G.E., Chang, L., Shetty, H.U., Krasuski, J.S., Rapoport, S.I., Schapiro,
 M.B., 2001. Brain metabolite concentration and dementia severity in Alzheimer's
 disease: a 1H MRS study. Neurology 57, 626–632.
- Hui, S.C., Saleh, M., Zoellner, H.J., Oeltzschner, G., Fan, H., Li, Y., Song, Y., Jiang, H., Near,
 J., Lu, H., 2022. MRSCloud: a Cloud-based MR Spectroscopy Tool for Basis Set
 Simulation. bioRxiv.
- Hupfeld, K.E., Hyatt, H.W., Alvarez Jerez, P., Mikkelsen, M., Hass, C.J., Edden, R.A.E., Seidler,
 R.D., Porges, E.C., 2021. In vivo brain glutathione is higher in older age and correlates
 with mobility. Cereb. Cortex 31, 4576–4594.
- Josephs, K.A., Duffy, J.R., Strand, E.A., Whitwell, J.L., Layton, K.F., Parisi, J.E., Hauser, M.F.,
 Witte, R.J., Boeve, B.F., Knopman, D.S., 2006. Clinicopathological and imaging
 correlates of progressive aphasia and apraxia of speech. Brain 129, 1385–1398.
- Kang, J.-S., Tian, J.-H., Pan, P.-Y., Zald, P., Li, C., Deng, C., Sheng, Z.-H., 2008. Docking of
 axonal mitochondria by syntaphilin controls their mobility and affects short-term
 facilitation. Cell 132, 137–148.
- Kantarci, K., Lowe, V., Przybelski, S.A., Senjem, M.L., Weigand, S.D., Ivnik, R.J., Roberts, R.,
 Geda, Y.E., Boeve, B.F., Knopman, D.S., 2011. Magnetic resonance spectroscopy, β amyloid load, and cognition in a population-based sample of cognitively normal older
 adults. Neurology 77, 951–958.
- 729 Kaplan, E., Goodglass, F., Weintraub, S., 2001. Boston Naming Test. Pro-ed Austin.
- Kim, G., Ahmadian, S.S., Peterson, M., Parton, Z., Memon, R., Weintraub, S., Rademaker, A.,
 Bigio, E., Mesulam, M.-M., Geula, C., 2016. Asymmetric pathology in primary
 progressive aphasia with progranulin mutations and TDP inclusions. Neurology 86, 627–
 636.
- Klose, U., 1990. In vivo proton spectroscopy in presence of eddy currents. Magn. Reson. Med.
 14, 26–30.
- Knibb, J.A., Xuereb, J.H., Patterson, K., Hodges, J.R., 2006. Clinical and pathological
 characterization of progressive aphasia. Ann. Neurol. 59, 156–165.
- Knopman, D.S., Kramer, J.H., Boeve, B.F., Caselli, R.J., Graff-Radford, N.R., Mendez, M.F.,
 Miller, B.L., Mercaldo, N., 2008. Development of methodology for conducting clinical
 trials in frontotemporal lobar degeneration. Brain 131, 2957–2968.
- Levin, O., Weerasekera, A., King, B.R., Heise, K.F., Sima, D.M., Chalavi, S., Maes, C., Peeters,
 R., Sunaert, S., Cuypers, K., 2019. Sensorimotor cortex neurometabolite levels as

743	correlate of motor performance in normal aging: evidence from a 1H-MRS study.
744	NeuroImage 202, 116050.
745	Liakakis, G., Nickel, J., Seitz, R., 2011. Diversity of the interior frontal gyrus—a meta-analysis of
746	neuroimaging studies. Benav. Brain Res. 225, 341–347.
/4/	Lim, T.S., Hong, Y.H., Choi, J.Y., Kim, H.S., Moon, S.Y., 2012. Functional investigation of
748	bilateral posterior cingulate gyri using multivoxel MR spectroscopy. Eur. Neurol. 67,
749	279–286.
750	Lin, A., Andronesi, O., Bogner, W., Choi, IY., Coello, E., Cudalbu, C., Juchem, C., Kemp, G.J.,
751	Kreis, R., Krššák, M., 2021. Minimum reporting standards for in vivo magnetic resonance
752	spectroscopy (MRSinMRS): experts' consensus recommendations. NMR Biomed. 34,
753	e4484.
754	Maes, C., Hermans, L., Pauwels, L., Chalavi, S., Leunissen, I., Levin, O., Cuypers, K., Peeters,
755	R., Sunaert, S., Mantini, D., 2018. Age-related differences in GABA levels are driven by
756	bulk tissue changes. Hum. Brain Mapp. 39, 3652–3662.
757	Marjańska, M., Emir, U.E., Deelchand, D.K., Terpstra, M., 2013. Faster metabolite 1H
758	transverse relaxation in the elder human brain. PloS One 8, e77572.
759	Marjańska, M., McCarten, J.R., Hodges, J., Hemmy, L.S., Grant, A., Deelchand, D.K., Terpstra,
760	M., 2017. Region-specific aging of the human brain as evidenced by neurochemical
761	profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe
762	using 1H magnetic resonance spectroscopy at 7 T. Neuroscience 354, 168–177.
763	Marjańska, M., McCarten, J.R., Hodges, J.S., Hemmy, L.S., Terpstra, M., 2019. Distinctive
764	neurochemistry in Alzheimer's Disease via 7 T in vivo magnetic resonance
765	spectroscopy. J. Alzheimers Dis. 68, 559–569.
766	McLeod, A.I., Xu, C., 2010. bestglm: Best subset GLM. URL HttpCRAN R-Proj. Orgpackage
767	Bestgim.
768	Mescher, M., Merkle, H., Kirsch, J., Garwood, M., Gruetter, R., 1998. Simultaneous in vivo
769	spectral editing and water suppression. NMR Biomed. Int. J. Devoted Dev. Appl. Magn.
770	Reson. Vivo 11, 266–272.
//1	Mesulam, M., 1982. Slowly progressive aphasia without generalized dementia. Ann. Neurol. Off.
772	J. Am. Neurol. Assoc. Child Neurol. Soc. 11, 592–598.
773	Mesulam, M., Wicklund, A., Jonnson, N., Rogalski, E., Leger, G.C., Rademaker, A., Weintraub,
774	S., Biglo, E.H., 2008. Alzheimer and frontotemporal pathology in subsets of primary
115	progressive apnasia. Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc. 63,
116	709–719. Mildeland M. Tannan O. Naam J. Maatafalas O.H. Data N.A. Eddan D.A. 2000. Camaatian
770	Mikkelsen, M., Tapper, S., Near, J., Mostorsky, S.H., Puts, N.A., Edden, R.A., 2020. Correcting
778	Frequency and phase offsets in MRS data using robust spectral registration. NMR
779	Biomed. 33, e4368.
780	Mitolo, M., Stanzani-Maserati, M., Manners, D.N., Capellari, S., Testa, C., Talozzi, L., Poda, R.,
781	Oppi, F., Evangelisti, S., Gramegna, L.L., Magarelli, S., Pantieri, R., Liguori, R., Lodi, R.,
782	Tonon, C., 2021. The Combination of Metabolic Posterior Cingulate Cortical
783	Abnormalities and Structural Asymmetries Improves the Differential Diagnosis Between
784	Primary Progressive Aphasia and Alzheimer's Disease. J. Alzheimer's Dis. 82, 1467–
785	1473. https://doi.org/10.3233/JAD-210211
786	Mosser, D.M., Edwards, J.P., 2008. Exploring the full spectrum of macrophage activation. Nat.
181	Rev. Immunol. 8, 958–969.
/ 88 700	Wurley, A.G., Kouse, M.A., Jones, P.S., Ye, K., Hezemans, F.H., O'Callagnan, C., Frangou, P.,
109	NOUTIZI, Z., RUB, U., Carpenter, T.A., 2020. GABA and glutamate deficits from frontetomore lober degeneration are accessisted with distribution. Brain 442, 2440
790	
191	3402.

792	Murley, A.G., Tsvetanov, K.A., Rouse, M.A., Jones, P.S., Sværke, K., Li, W., Carpenter, A.,
793	Rowe, J.B., 2022. Proton magnetic resonance spectroscopy in frontotemporal lobar
794	degeneration-related syndromes. Neurobiol. Aging 111, 64–70.
795	Nestor, P.J., Balan, K., Cheow, H.K., Fryer, T.D., Knibb, J.A., Xuereb, J.H., Hodges, J.R., 2007.
796 707	Nuclear imaging can predict pathologic diagnosis in progressive nonfluent aphasia.
797	Neuroph C. Ciuffre A. Cala J. Bell T. Carleon H.J. MacMaster F.B. Kirten A. Harria
790	NWAION, C., Gluine, A., Cole, L., Dell, T., Canson, H.L., MacMaster, F.F., Kinon, A., Hams,
800	Childron: A pilot study, PLOS ONE 15, o0222620
801	https://doi.org/10.1371/journal.pone.0222620
802	Oeltzschner G. Wijtenburg S.A. Mikkelsen M. Edden R.A. Barker P.B. Joo. I.H.
803	Leoutsakos J-M S Rowland I M Workman C I Smith G S 2019
804	Neurometabolites and associations with cognitive deficits in mild cognitive impairment: a
805	magnetic resonance spectroscopy study at 7 Tesla. Neurobiol. Aging 73, 211–218
806	Oeltzschner, G., Zöllner, H.J., Hui, S.C., Mikkelsen, M., Saleh, M.G., Tapper, S., Edden, R.A.
807	2020. Osprev: Open-source processing, reconstruction & estimation of magnetic
808	resonance spectroscopy data. J. Neurosci. Methods 343, 108827.
809	Ohm, D.T., Kim, G., Gefen, T., Rademaker, A., Weintraub, S., Bigio, E.H., Mesulam, MM.,
810	Rogalski, E., Geula, C., 2019. Prominent microglial activation in cortical white matter is
811	selectively associated with cortical atrophy in primary progressive aphasia. Neuropathol.
812	Appl. Neurobiol. 45, 216–229.
813	Pagnoni, I., Gobbi, E., Premi, E., Borroni, B., Binetti, G., Cotelli, M., Manenti, R., 2021.
814	Language training for oral and written naming impairment in primary progressive
815	aphasia: A review. Transl. Neurodegener. 10, 1–34.
816	Pfefferbaum, A., Adalsteinsson, E., Spielman, D., Sullivan, E.V., Lim, K.O., 1999. In vivo
817	spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large
818	volumes of brain gray and white matter: Effects of normal aging. Magn. Reson. Med. Off.
819	J. Int. Soc. Magn. Reson. Med. 41, 276–284.
820	Pinheiro, J.C., Bates, D.M., 2000. Theory and computational methods for linear mixed-effects
821	models. MixEff. Models -PLUS 57–96.
822	Porges, E.C., Woods, A.J., Edden, R.A., Puts, N.A., Harris, A.D., Chen, H., Garcia, A.M.,
823	Seider, I.R., Lamb, D.G., Williamson, J.B., 2017a. Frontal gamma-aminobutyric acid
824	concentrations are associated with cognitive performance in older adults. Biol.
825	Psychiatry Cogn. Neurosci. Neuroimaging 2, 38–44.
820 927	Porges, E.C., Woods, A.J., Lamb, D.G., Williamson, J.B., Cohen, R.A., Edden, R.A., Hams,
021	A.D., 2017b. Impact of itsue conection strategy on GABA-edited MRS indings. Neuroimage 162, 240, 256
020 820	Proiß D Billotto OV Schneider A Spoterne N Nester D I 2010 The atrenby pattern in
830	Alzheimer-related PPA is more widespread than that of the frontotemporal lobar
831	degeneration associated variants. NeuroImage Clin. 24, 101004
832	https://doi.org/10.1016/i.nicl.2019.101994
833	R Core Team 2021 R: A language and environment for statistical computing R Foundation for
834	Statistical Computing Vienna Austria
835	Rabinovici, G.D., Jagust, W.J., Furst, A.J., Ogar, J.M., Racine, C.A., Mormino, E.C., O'Neil,
836	J.P., Lal, R.A., Dronkers, N.F., Miller, B.L., 2008. Aß amvloid and glucose metabolism in
837	three variants of primary progressive aphasia. Ann. Neurol. 64, 388–401.
838	Rackayova, V., Cudalbu, C., Pouwels, P.J., Braissant, O., 2017. Creatine in the central nervous
839	system: From magnetic resonance spectroscopy to creatine deficiencies. Anal. Biochem.
840	529, 144–157.
841	Rae, C.D., 2014. A guide to the metabolic pathways and function of metabolites observed in
842	human brain 1H magnetic resonance spectra. Neurochem. Res. 39, 1–36.

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

843	Ratai, EM., Annamalai, L., Burdo, T., Joo, CG., Bombardier, J.P., Fell, R., Hakimelahi, R.,
844	He, J., Lentz, M.R., Campbell, J., 2011. Brain creatine elevation and N-acetylaspartate
845	reduction indicates neuronal dysfunction in the setting of enhanced glial energy
846	metabolism in a macaque model of NeuroAIDS. Magn. Reson. Med. 66, 625–634.
847	Reyngoudt, H., Claeys, I., Vlerick, L., Verleden, S., Acou, M., Deblaere, K., De Deene, Y.,
848	Audenaert, K., Goethals, I., Achten, E., 2012. Age-related differences in metabolites in
849	the posterior cingulate cortex and hippocampus of normal ageing brain: a 1H-MRS
850	study. Eur. J. Radiol. 81, 6223–6231.
851	Riese, F., Gleti, A., Zoich, N., Henning, A., O'Gorman, R., Kalin, A.M., Len, S.E., Buck, A.,
852	vvarnock, G., Edden, R.A., 2015. Posterior cingulate y-aminobutyric acid and
853	giutamate/giutamine are reduced in amnestic mild cognitive impairment and are
804 955	unrelated to amyloid deposition and apolipoprotein E genotype. Neurobiol. Aging 36, 53–
800 956	09. Rogalski E. Cabia D. Harrison T.M. Wienska C. Waintraub S. Masulam M. M. 2011
000	Rogalski, E., Cobia, D., Harrison, T.M., Wieneke, C., Weinitaub, S., Mesularri, MM., 2011.
001	Progression of language decline and control alrophy in subtypes of primary progressive
000 950	Pogolski E Cobio D Mortorstock & Podomakor A Wionako C Wointroub S Mosulam
860	M-M 2014 Asymmetry of cortical decline in subtypes of primary progressive appasia
861	Nourology 83, 1184, 1101
862	Ross A Sachdey P.S. Wen W. Valenzuela M Brodaty H 2005 Cognitive correlates
863	of 1H MRS measures in the healthy elderly brain Brain Res Bull 66 9-16
864	RStudio Team 2021 RStudio: Integrated Development Environment for R RStudio PBC
865	Roston MA
866	Runsingh R Borrie M Smith M Wells JJ Bartha R 2011 Reduced hippocampal
867	dutamate in Alzheimer disease Neurobiol Aging 32 802–810
868	Sasaki R. Otsuru N. Miyaguchi S. Kojima S. Watanabe H. Ohno K. Sakurai N.
869	Kodama N. Sato D. Onishi H. 2021 Influence of Brain-Derived Neurotrophic Factor
870	Genotype on Short-Latency Afferent Inhibition and Motor Cortex Metabolites. Brain Sci.
871	11. 395. https://doi.org/10.3390/brainsci11030395
872	Saunders, D.E., Howe, F.A., van den Boogaart, A., Griffiths, J.R., Brown, M.M., 1999, Aging of
873	the adult human brain: in vivo quantitation of metabolite content with proton magnetic
874	resonance spectroscopy. J. Magn. Reson. Imaging Off. J. Int. Soc. Magn. Reson. Med.
875	9, 711–716.
876	Tastevin, M., Lavoie, M., de la Sablonnière, J., Carrier-Auclair, J., Laforce, R., 2021. Survival in
877	the Three Common Variants of Primary Progressive Aphasia: A Retrospective Study in a
878	Tertiary Memory Clinic. Brain Sci. 11, 1113. https://doi.org/10.3390/brainsci11091113
879	Tkáč, I., Starčuk, Z., Choi, IY., Gruetter, R., 1999. In vivo 1H NMR spectroscopy of rat brain at
880	1 ms echo time. Magn. Reson. Med. Off. J. Int. Soc. Magn. Reson. Med. 41, 649–656.
881	Tombaugh, T., 1999. Normative Data Stratified by Age and Education for Two Measures of
882	Verbal Fluency FAS and Animal Naming. Arch. Clin. Neuropsychol. 14, 167–177.
883	https://doi.org/10.1016/S0887-6177(97)00095-4
884	Tsapkini, K., Frangakis, C., Gomez, Y., Davis, C., Hillis, A.E., 2014. Augmentation of spelling
885	therapy with transcranial direct current stimulation in primary progressive aphasia:
886	Preliminary results and challenges. Aphasiology 28, 1112–1130.
887	https://doi.org/10.1080/02687038.2014.930410
888	Tsapkini, K., Webster, K.T., Ficek, B.N., Desmond, J.E., Onyike, C.U., Rapp, B., Frangakis,
889	C.E., Hillis, A.E., 2018. Electrical brain stimulation in different variants of primary
890	progressive aphasia: A randomized clinical trial. Alzheimers Dement. Transl. Res. Clin.

891 Interv. 4, 461–472.

- Urenjak, J., Williams, S.R., Gadian, D.G., Noble, M., 1993. Proton nuclear magnetic resonance
 spectroscopy unambiguously identifies different neural cell types. J. Neurosci. 13, 981–
 989.
- Wang, H., Tan, L., Wang, H.-F., Liu, Y., Yin, R.-H., Wang, W.-Y., Chang, X.-L., Jiang, T., Yu, J.T., 2015. Magnetic resonance spectroscopy in Alzheimer's disease: systematic review
 and meta-analysis. J. Alzheimers Dis. 46, 1049–1070.
- Wansapura, J.P., Holland, S.K., Dunn, R.S., Ball Jr, W.S., 1999. NMR relaxation times in the
 human brain at 3.0 tesla. J. Magn. Reson. Imaging Off. J. Int. Soc. Magn. Reson. Med.
 900 9, 531–538.
- Wicklund, M.R., Duffy, J.R., Strand, E.A., Machulda, M.M., Whitwell, J.L., Josephs, K.A., 2014.
 Quantitative application of the primary progressive aphasia consensus criteria.
 Neurology 82, 1119–1126. https://doi.org/10.1212/WNL.00000000000261
- Wilson, M., Andronesi, O., Barker, P.B., Bartha, R., Bizzi, A., Bolan, P.J., Brindle, K.M., Choi, I. Y., Cudalbu, C., Dydak, U., 2019. Methodological consensus on clinical proton MRS of
 the brain: Review and recommendations. Magn. Reson. Med. 82, 527–550.
- Zahr, N.M., Mayer, D., Rohlfing, T., Chanraud, S., Gu, M., Sullivan, E.V., Pfefferbaum, A., 2013.
 In vivo glutamate measured with magnetic resonance spectroscopy: behavioral
 correlates in aging. Neurobiol. Aging 34, 1265–1276.
- Zeydan, B., Deelchand, D.K., Tosakulwong, N., Lesnick, T.G., Kantarci, O.H., Machulda, M.M.,
 Knopman, D.S., Lowe, V.J., Jack Jr, C.R., Petersen, R.C., 2017. Decreased glutamate
 levels in patients with amnestic mild cognitive impairment: An sLASER proton MR
 spectroscopy and PiB-PET study. J. Neuroimaging 27, 630–636.
- 2hang, N., Song, X., Bartha, R., Beyea, S., D'Arcy, R., Zhang, Y., Rockwood, K., 2014.
 Advances in high-field magnetic resonance spectroscopy in Alzheimer's disease. Curr.
 Alzheimer Res. 11, 367–388.
- 2hang, Z., 2016. Variable selection with stepwise and best subset approaches. Ann. Transl.
 Med. 4.
- Zöllner, H.J., Považan, M., Hui, S.C., Tapper, S., Edden, R.A., Oeltzschner, G., 2021.
 Comparison of different linear-combination modeling algorithms for short-TE proton spectra. NMR Biomed. 34, e4482.
- Zöllner, H.J., Tapper, S., Hui, S.C., Barker, P.B., Edden, R.A., Oeltzschner, G., 2022.
 Comparison of linear combination modeling strategies for edited magnetic resonance
 spectroscopy at 3 T. NMR Biomed. 35, e4618.
- 925